Physiotensis, 0.4 mg 28 pcs

An antihypertensive agent. The mechanism of action of moxonidine is associated mainly with its effect on central parts of BP regulation. Moxonidine is an agonist of mainly imidazoline receptors.

With excitation of the above receptors of the neurons of the solitary tract, moxonidine through the system of inhibitory interneurons promotes inhibition of the activity of the vasomotor center and thus – reduction of descending sympathetic effects on the cardiovascular system. BP (systolic and diastolic) decreases gradually.

Moxonidine differs from other sympatholytic hypotensive agents in its lower affinity for α₂-adrenoreceptors, which explains the lower likelihood of developing sedative effects and dry mouth.

Moxonidine increases insulin sensitivity index (compared with placebo) by 21% in patients with obesity, insulin resistance and moderate arterial hypertension.

Indications

Arterial hypertension.

Active ingredient

Composition

1 tablet moxonidine 0.4 mg

Associated substances:

lactose monohydrate – 95.6 mg,

povidone – 0.7 mg,

crospovidone – 3 mg,

magnesium stearate – 0.3 mg.

Shell composition:

hypromellose – 1.3 mg,

ethylcellulose – 1.2 mg,

macrogol – 0.25 mg,

talc – 0.875 mg,

red iron oxide dye (E172) – 0.125 mg,

titanium dioxide (E171) – 1.25 mg.

How to take, the dosage

It is taken orally. The initial dose is on average 200 mcg orally once daily. The maximum single dose is 400 mcg. Individual adjustment of the daily dose depending on the tolerability of therapy is necessary. The maximum daily dose is 600 mcg in 2 doses.

For patients with moderate to severe renal insufficiency and those on hemodialysis, the initial dose is 200 mcg/day. If necessary and if well tolerated, the daily dose can be increased to a maximum of 400 mcg.

Interaction

The co-administration of moxonidine with other hypotensive agents leads to additive effects.

Tricyclic antidepressants may decrease the effectiveness of centrally acting hypotensive drugs, therefore it is not recommended to take them together with moxonidine.

Moxonidine may increase the effects of tricyclic antidepressants, tranquilizers, ethanol, sedatives, and hypnotics.

Moxonidine may moderately improve impaired cognitive function in patients receiving lorazepam.

Moxonidine may increase the sedative effect of benzodiazepine derivatives when prescribed concomitantly.

Moxonidine is excreted by tubular secretion. Therefore, its interaction with other drugs excreted by tubular secretion cannot be excluded.

Special Instructions

Particular caution should be exercised when using moxonidine in patients with Grade I AV blockade (risk of bradycardia); severe coronary artery disease and unstable angina pectoris (insufficient experience of use); renal impairment.

If withdrawal of concomitant beta-adrenoblockers and moxonidine is necessary, the beta-adrenoblockers should be withdrawn first and moxonidine only after several days.

There is currently no evidence that discontinuation of moxonidine causes an increase in BP. However, abrupt discontinuation of moxonidine is not recommended; the dose should be reduced gradually over 2 weeks.

Impact on driving and operating machinery

Patients should be careful during treatment to engage in potentially hazardous activities requiring concentration and high speed of psychomotor reactions.

Contraindications

Side effects

CNS disorders: often – headache, dizziness (vertigo), somnolence; rarely – fainting.

Cardiovascular system disorders: infrequent – marked BP decrease, orthostatic hypotension, bradycardia.

Digestive system disorders: very frequently – dry mouth; frequently – diarrhea, nausea, vomiting, dyspepsia.

Skin and subcutaneous tissue: often – skin rash, itching; infrequent – angioedema.

Psychiatric disorders: often – insomnia; infrequent – nervousness.

Hearing organ and labyrinth disorders: infrequent – tinnitus.

Muscular system: often – back pain; infrequent – pain in the neck.

The body in general: often – asthenia; infrequent – peripheral edema.

Similarities